<p>Humacyte Inc. 宣布了一项为期五年的回顾性分析结果，研究了四肢动脉损伤患者的医院费用、支付者成本和医疗资源利用情况。研究发现，初次四肢动脉损伤修复的平均医院费用为每位患者 316,600 美元。可预防的并发症，如截肢和导管感染，分别使医院费用增加约 493,000 美元和 590,000 美元。分析还表明，Humacyte 的 Symvess（一种无细胞组织工程血管）显示出低感染率和高肢体挽救率。所有数据均在 Symvess 获得 FDA 批准之前收集，反映了其商业化前的医疗经济情况。该结果已由公司提前公布。免责声明：本新闻简报由公共技术公司（PUBT）使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。Humacyte Inc. 于 2026 年 1 月 8 日通过 GlobeNewswire 发布了用于生成本新闻简报的原始内容（参考 ID：9621911），并对此信息承担全部责任。© 版权 2026 - 公共技术公司（PUBT）</p>

HUMA

<p>Humacyte Inc. 报告了关于肢体动脉损伤修复成本的五年分析结果。每位患者的平均医院费用为 316,600 美元，诸如截肢和感染等可预防并发症显著提高了成本。研究强调，Humacyte 的 Symvess，一种无细胞组织工程血管，显示出低感染率和高肢体挽救率。这些结果在 Symvess 获得 FDA 批准和商业化之前就已分享</p>

<p>Humacyte Inc. announced the results of a five-year retrospective analysis examining hospital charges, payer costs, and healthcare resource utilization in patients with extremity arterial injury. The study found that the average hospital charge for initial extremity arterial injury repair was $316,600 per patient. Preventable complications, such as amputation and conduit infection, increased hospital charges by approximately $493,000 and $590,000 per patient, respectively. The analysis also indicated that Humacyte’s Symvess, an acellular tissue engineered vessel, demonstrated low rates of infection and high rates of limb salvage. All data were collected prior to FDA approval of Symvess and reflect healthcare economics before its commercialization. The results have already been announced by the company. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621911) on January 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>
<div class="lb-trans"><p>Humacyte Inc. 宣布了一项为期五年的回顾性分析结果，研究了四肢动脉损伤患者的医院费用、支付者成本和医疗资源利用情况。研究发现，初次四肢动脉损伤修复的平均医院费用为每位患者 316,600 美元。可预防的并发症，如截肢和导管感染，分别使医院费用增加约 493,000 美元和 590,000 美元。分析还表明，Humacyte 的 Symvess（一种无细胞组织工程血管）显示出低感染率和高肢体挽救率。所有数据均在 Symvess 获得 FDA 批准之前收集，反映了其商业化前的医疗经济情况。该结果已由公司提前公布。免责声明：本新闻简报由公共技术公司（PUBT）使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。Humacyte Inc. 于 2026 年 1 月 8 日通过 GlobeNewswire 发布了用于生成本新闻简报的原始内容（参考 ID：9621911），并对此信息承担全部责任。© 版权 2026 - 公共技术公司（PUBT）</p>
</div>

Humacyte 报告称 Symvess 在修复肢体动脉损伤时减少了昂贵的并发症